bioAffinity Technologies (BIAF) Investor presentation summary

Market landscape and need

• Lung cancer is the leading cause of cancer-related deaths globally, with 2.48 million new cases and 1.8 million deaths annually.

• Major screening gaps exist, with 19.3 million Americans recommended for annual screening and up to 34 million at risk in the EU.

• The lung cancer diagnostics market is projected to grow from $20B in 2023 to $38B by 2034, at a 7.23% CAGR.

• Early detection significantly improves survival, with a 92% 10-year survival rate for Stage I patients treated within a month.

CyPath Lung platform and technology

• CyPath Lung uses AI-driven analysis of flow cytometry data from sputum samples for noninvasive lung cancer detection.

• Demonstrates 92% sensitivity, 87% specificity, 99% negative predictive value, and 88% accuracy for nodules <20mm.

• Enables at-home sample collection and delivers results within three days of lab receipt.

• Outperforms or matches standard diagnostic procedures in sensitivity and specificity.

• Proprietary AI platform rapidly identifies cancer-indicative cell populations in minutes.

Clinical validation and case studies

• Case studies show CyPath Lung detects cancer at curative Stage 1A and helps avoid unnecessary invasive procedures.

• Demonstrated ability to detect recurrence and new malignancies during surveillance, enabling earlier intervention.

• Provides actionable results that increase physician confidence in patient care.